Research Topics
| Neveen At HamdySummaryAffiliation: Leiden University Medical Center Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Limitations of Tc99m-MIBI-SPECT imaging scans in persistent primary hyperparathyroidismJanneke E Witteveen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
World J Surg 35:128-39. 2011....- Challenges and pitfalls in the management of parathyroid carcinoma: 17-year follow-up of a case and review of the literatureJanneke E Witteveen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
Horm Cancer 1:205-14. 2010..In this paper, we report the challenges and pitfalls we encountered in the management of our patient over nearly two decades of follow-up and review recent literature on the topic... - The psychological burden of an initially unexplained illness: patients with sternocostoclavicular hyperostosis before and after delayed diagnosisWillem A Van der Kloot
Institute of Psychology, Leiden University, Leiden, The Netherlands
Health Qual Life Outcomes 8:97. 2010..Secondly, to investigate the relationships between the pre-diagnostic and the current psychological conditions of confirmed SCCH patients... - Calcium and bone metabolism pre- and post-kidney transplantationNeveen A T Hamdy
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Endocrinol Metab Clin North Am 36:923-35; viii. 2007..Therapeutic strategies to effectively and safely decrease skeletal morbidity after kidney transplantation are not yet clearly established... - Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosisNeveen A T Hamdy
Leiden University Medical Center, Department of Endocrinology and Metabolic Diseases, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Curr Opin Investig Drugs 8:299-303. 2007..The potential of RANKL as a therapeutic target in the treatment of osteoporosis is discussed in this review... - A patient with persistent primary hyperparathyroidism due to a second ectopic adenomaNeveen At Hamdy
Department of Endocrinology and Metabolic Diseases at the Leiden University Medical Center, Leiden, The Netherlands
Nat Clin Pract Endocrinol Metab 3:311-5. 2007..Planar (99m)Tc-sestamibi and ultrasound scans failed to provide conclusive localization for another enlarged parathyroid gland. The patient was referred to our Endocrinology Unit for further investigations and management... - Strontium ranelate improves bone microarchitecture in osteoporosisNeveen A T Hamdy
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Rheumatology (Oxford) 48:iv9-13. 2009..No attempt is made at comparing the effects of strontium ranelate on bone microarchitecture with that of other anti-resorptive or anabolic osteoporosis agents... - Osteoprotegerin as a potential therapy for osteoporosisNeveen A T Hamdy
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Curr Osteoporos Rep 3:121-5. 2005..Data are still very scarce, however, and much remains to be uncovered before novel strategies capable of modulating the RANKL/OPG signaling pathway could be safely and effectively used in the management of osteoporosis... - Denosumab: RANKL inhibition in the management of bone lossN A T Hamdy
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Drugs Today (Barc) 44:7-21. 2008..The potential of denosumab to prevent bone loss has also been demonstrated in malignancy-induced bone loss. Ongoing studies in rheumatoid arthritis are also promising... - Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of boneSerge C L M Cremers
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 18:868-75. 2003..Such approaches can lead to improved patient care and individualization of treatment of Paget's disease with bisphosphonates... - Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantationYves F C Smets
Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
Kidney Int 66:2070-6. 2004..Data are scarce on preexisting skeletal morbidity or the long-term effects of SPK on bone mass and risk of fractures... - [Antitumour effects of bisphosphonates in breast cancer]Saskia van de Ven
Leids Universitair Medisch Centrum, Leiden, afd Klinische Oncologie, The Netherlands
Ned Tijdschr Geneeskd 154:A1951. 2010..The role of bisphosphonates in primary neoadjuvant treatment of breast cancer is promising, but must be further investigated... - Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegalyNienke R Biermasz
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Leiden, The Netherlands
Eur J Endocrinol 152:53-60. 2005..Data on BMD are not available after successful treatment of acromegaly. Whether the positive effect of GH excess on bone mass is maintained in the long term after clinical and biochemical cure of acromegaly remains to be established... - Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up studyNienke R Biermasz
Department of Endocrinology and Metabolism, Leiden University Medical Centre, Leiden, The Netherlands
Clin Endocrinol (Oxf) 60:568-75. 2004..It is also not known whether osteoporotic GH-deficient patients may require additional antiresorptive drugs and whether this treatment would be effective concomitantly with GH replacement... - Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapyMarelise E M W Eekhoff
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Bone 33:831-8. 2003..In addition, we identified and quantified determinants of the response to bisphosphonate that can help in improving the management of patients with Paget's disease with bisphosphonates... - Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extensionCaroline Brumsen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
J Bone Miner Res 17:1057-64. 2002..One hundred fifty milligrams daily of pamidronate is an effective and safe treatment of women and men with established osteoporosis... - Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's diseaseSerge C L M Cremers
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
Osteoporos Int 16:1727-30. 2005..This adequacy is confirmed by appropriate suppression of bone resorption and increase in lumbar spine BMD. These data hold significant implications for the clinical management of patients with Crohn's disease and osteoporosis... - Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapyCaroline Brumsen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
J Bone Miner Res 17:567-9. 2002 - Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studiesAndrea Giusti
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
Bone 47:169-80. 2010.... - Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnoverAntoon H van Lierop
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 26:2804-11. 2011..Further studies are needed to clarify the role of sclerostin on bone resorption... - Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeletonVidya Soerdjbalie-Maikoe
Department of Urology, Leiden University Medical Center, Leiden, The Netherlands
Eur J Nucl Med Mol Imaging 29:494-8. 2002..The use of these agents opens new avenues in the difficult management of patients with advanced prostate cancer who are most at risk of developing SCC... - Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancerVidija Soerdjbalie-Maikoe
Department of Urology, Leiden University Medical Center, Leiden, The Netherlands
Eur J Nucl Med Mol Imaging 31:958-63. 2004..Our data suggest that there is still a place for bone scintigraphy in the management of hormone-refractory prostate cancer... - Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX genePolyzois Makras
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
J Clin Endocrinol Metab 93:1386-9. 2008..X-linked hypophosphatemic rickets (XLH) is characterized by hypophosphatemia and growth retardation. Early diagnosis and treatment improve growth... - Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in managementRob C M Pelger
Department of Urology, Leiden University Medical Center, The Netherlands
Bone 36:1-5. 2005..In this malignancy in which metastases have a predilection for bone, failure to recognize osteomalacia can only result in significantly increasing the burden of skeletal complications... - The role of selective venous sampling in the management of persistent hyperparathyroidism revisitedJanneke E Witteveen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Eur J Endocrinol 163:945-52. 2010..The aim of our study is to determine the accuracy of selective venous sampling (SVS) for parathyroid hormone (PTH) in localizing residual hyperactive parathyroid glands in patients with persistent or recurrent hyperparathyroidism... - No recurrence of sporadic primary hyperparathyroidism when cure is established 6 months after parathyroidectomyJanneke E Witteveen
Departments of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Eur J Endocrinol 162:399-406. 2010..The aim of our study was to establish the cure rate and its maintenance in the long-term after parathyroidectomy (PTx) in patients with sporadic PHPT... - The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancerRob C M Pelger
Departments of Urology, Leiden University Medical Center, The Netherlands
Prostate 50:119-24. 2002.... - Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donorBrian M Nicholls
Department of Medicine, Bone and Mineral Centre, University College London, United Kingdom
J Bone Miner Res 20:2264-70. 2005..CONCLUSIONS: This is the first case reported in which a successful hematopoietic engraftment failed to correct an osteopetrotic skeletal defect, and this finding may be credited to the age at which the child was transplanted... - Bone mineral density in sclerosteosis; affected individuals and gene carriersJessica C Gardner
Division of Human Genetics, Faculty of Health Sciences, University of Cape Town, South Africa
J Clin Endocrinol Metab 90:6392-5. 2005..In the present study we assessed the effect of variable expression of the genetic defect on bone mineral density (BMD) in patients and carriers of the determinant gene...